Abstract. To evaluate the secretory regulation of 19-hydroxyandrostenedione (19-OH-AD), its plasma concentration was measured before and after stimulation and inhibition tests for the ACTH-adrenal axis and the renin-angiotensin system in 50 normal subjects. Basal levels of plasma 19-OH-AD did not correlate with either those of plasma renin activity (PRA) or the plasma aldosterone concentration (PAC), but positively correlated with those of plasma cortisol. Plasma 19-OH-AD was stimulated by 0.25 mg ACTH-(1-24) and was suppressed by 1mg dexamethasone (DEX) as were plasma cortisol and PAC. On the other hand, with 2-h standing alone or iv 40mg furosemide plus 2-h standing, plasma 19-OH-AD and cortisol did not increase but PRA and PAC did. With iv furosemide plus 2-h standing with 3mg DEX pretreatment, plasma 19-OH-AD and cortisol did not respond either, but PRA and PAC increased. With 25mg oral captopril following 1-h standing with 3mg DEX pretreatment, plasma 19-OH-AD and cortisol did not change but PAC decreased. These results indicate that the secretion of 19-OH-AD is mainly under the control of the ACTH-adrenal axis rather than the renin-angiotensin system.
THE STEROID,
19-hydroxyandrost-4-ene-3,17-dione (19-OH-AD), has been reported by Sekihara to be a more potent sodium-retaining and hypertensinogenic agent than deoxycorticosterone acetate in intact rats [1] [2] [3] . Simultaneous administration of 19-OH-AD and subthreshold dose of aldosterone increases the mineralocorticoid action of aldosterone in adrenalectomized rats, but 19-OH-AD alone does not [4] . Adrenal immunohistochemistry in dogs revealed that 19-0H-AD, as well as the other C19 steroids, is mainly produced in the zona reticularis [5] .
Clinical studies by Sekihara et al. on the secreting mechanism of the secretion of 19-OH-AD in normal man have been done. They have shown that 19-OH-AD is secreted directly from the adrenal cortex and its secretion is under the control of both the ACTH-adrenal axis and the renin-angiotensin system [3, 6, 7] . Their data in normal subjects, however, did not necessarily show a dose-dependent response of 19-OH-AD to angiotensin II infusion [7] . Furthermore, during upright posture for 3 h in normal subjects, it decreased in some, although PRA and PAC increased in all [7] . In the in vitro study by Higuchi and colleagues [8] , the production of 19-OH-AD from cultured human adrenal cells was promoted in the presence of ACTH but not angiotensin II.
In the present study, we measured the plasma 
Results
Basal hormone levels ( Table 2) There was no significant difference according to sex in any of the plasma hormones measured. Basal levels of plasma 19-OH-AD did not correlate with those of PRA or with those of PAC but positively correlated with plasma cortisol (r=0.34, P<0.05).
ACTH stimulation test (Table 3 and Fig. 1-A DEX suppression test (Table 3 and Fig. 1-B Intravenous furosemide plus 2-h standing (Table 3) PRA and PAC increased significantly (P<0.01 and P<0.01, respectively) and the changes were greater than during 2-h standing alone but plasma 19-OH-AD and plasma cortisol did not change significantly.
Intravenous furosemide plus 2-h standing with DEX pretreatment (Table 3) Pretreatment with DEX suppressed basal plasma levels of 19-OH-AD and cortisol (P<0.01 and P<0.01, respectively, vs. no DEX pretreatment). However, the suppression of plasma cortisol was A) B) more evident than plasma 19-OH-AD as described in the result of DEX suppression test. Following furosemide plus 2-h standing, PRA and PAC increased significantly (P<0.01 and P<0.01, respectively) but there was no significant change in plasma levels of 19-OH-AD and cortisol.
Captopril test following 1-h standing with DEX pretreatment (Table 3 and Fig. 3 )
Basal PRA and PAC increased significantly (P<0.01 and P<0.01, respectively, vs. DEX pretreatment alone) due to the preceding 1-h standing even in subjects pretreated with DEX. On the other hand, plasma levels of 19-OH-AD and cortisol after 1-h standing were suppressed by DEX pretreatment (P<0.01 and P<0.01, respectively, vs. no DEX pretreatment). The subsequent captopril administration raised PRA and lowered PAC significantly (P<0.01 and P<0.01, respectively). In contrast, it did not cause any change in the plasma level of 19-OH-AD or cortisol.
Discussion
The present data suggested that the secretion of 19-OH-AD in normal subjects is closely dependent on the ACTH-adrenal axis: 1) basal levels of plasma 19-OH-AD positively correlated with those of plasma cortisol, and 2) ACTH-(1-24) stimulated and DEX suppressed plasma 19-OH-AD as well as plasma cortisol although the suppressive effect of DEX on plasma 19-OH-AD was the lesser. The latter finding was consistent with that of Sekihara et al. [3, 6, 7] . On the other hand, the regulation of plasma 19-OH-AD by the renin-angiotensin system seems to be less potent. Basal plasma levels of 19-OH-AD did not correlate with either basal PRA or PAC. With regard to stimulation tests such as 2-h standing alone, iv furosemide plus 2-h standing and iv furosemide plus 2-h standing with DEX pretreatment, there was no significant response in plasma 19-OH-AD and cortisol while PRA and PAC increased. Captopril administration following 1-h standing with DEX pretreatment did not [7] . Similar analysis of our data with 2-h standing showed that in Group I (n=6) whose plasma 19-OH-AD decreased obviously, PAC rose significantly, and in Group II (n=3) whose plasma 19-OH-AD did not change, the change in PAC could not be analyzed but it had a tendency to increase. It seemed that the only difference between our results and those of Sekihara et al. [7] was that the increase in plasma 19-OH-AD in Group II was not significant in our study. This suggests that there is a mechanism of 19-OH-AD secretion in connection with the concomitant increase in angiotensin II and/or aldosterone as previously suggested [7] . However, although the amount in Group II was small, the basal PAC in Group I was not different from that in Group II, and the PAC after 2-h standing in Group II was rather higher than that in Group I (P<0.05). This finding did not necessarily support the speculations by Sekihara et al. [7] . A possible explanation In summary, our results suggested that 19-OH-AD secretion is mainly controlled by the ACTHadrenal axis rather than the renin-angiotensin system in normal subjects.
